The Ministry of Finance has launched anti-dumping and anti-subsidy investigations into steel products from China sold on the local market in a bid to protect the interests of Taiwanese firms.
The ministry on Tuesday said in a statement that Chinese products being looked at by the anti-dumping investigation include galvanized steel, carbon steel plates and cold-rolled stainless steel, while the anti-subsidy probe involves hot-rolled stainless steel and cold-rolled carbon steel.
In addition to protecting local steel manufacturers, the probe aims to provide Taiwan with an additional bargaining chip in talks with the US as it seeks an exemption from Washington’s 25 percent tariff on imported steel and a 10 percent tariff on aluminum imposed last month, the ministry said.
Taiwan has no intention of getting involved in a trade war between the US and China, but launching a probe into Chinese steel products is expected to ensure that Beijing cannot use Taiwan as a transit point to sell its cheap steel products in the US market, Customs Administration Deputy Director-General Hsieh Ling-yuan (謝玲媛) said.
On March 8, US President Donald Trump signed an order under Section 232 of the US’ Trade Expansion Act of 1962 to impose additional tariffs on imported steel and aluminum.
The duties took effect 15 days after the signing.
Despite negotiations between Taiwanese and US trade officials last month, Taipei was not included on the list of exempt nations.
The government has said that it would continue to seek an exemption through more talks with the US.
After a meeting of the ministry’s tariff review task force on Wednesday last week, Hsieh said the ministry suspects that these Chinese steel products are part of unfair trade practices that could harm Taiwanese manufacturers.
The ministry said it also consulted with the Ministry of Economic Affairs before deciding to launch its investigations into Chinese steel imports.
Just a few years ago, the millennial generation — generally defined as those born from the early 1980s through the mid-1990s — was synonymous with youthful rebellion. However, now, as the millennials ease into early middle age, they are finding their path out of their parents’ basement to be a lot harder than it was for earlier generations. The fundamental problem is that millennials are not building wealth. The wealth of the median US household headed by someone 35 or younger has actually shrunk in inflation-adjusted terms since the mid-2000s, even as the wealth of older Americans has continued to grow. An
Apple Inc’s decision to stop using Intel Corp processors in its Mac computers and switching to its own chips might benefit Taiwan Semiconductor Manufacturing Co (TSMC, 台積電) and boost Taiwan’s high-tech exports, Australia and New Zealand Banking Group (ANZ) said in a note on Tuesday. The US tech giant announced the “Apple silicon” initiative at its annual Worldwide Developers’ Conference, which started on Monday. The company said the first Mac powered by its own chips would debut by the end of this year and all product lines might shift to the new architecture in the next two years. TSMC is likely to
Gogoro Inc (睿能創意) yesterday launched its first electric bicycle, the Gogoro Eeyo 1, in Taiwan, after unveiling the bike in New York in late May and in France on Tuesday. The company said it would also introduce the series in other European countries such as Germany and the Netherlands. The “Eeyo project” is the fourth of Gogoro’s eight projects that concentrate on smart transportation, which includes Gogoro’s electric scooter, battery swap system and electric scooter sharing service, company founder and chief executive officer Horace Luke (陸學森) told a media briefing in Taipei. “There are various types of city commuters. We will not
EXPERIMENTAL DRUG: While news about a COVID-19 vaccine is more eye-catching, developing a treatment would be more viable, the Senhwa boss said Senhwa Biosciences Inc (生華科) aims to raise NT$1.5 billion (US$50.57 million) by issuing 15 million new common shares in the third quarter of this year to fund the research of new drugs, including the experimental drug Silmitasertib for the treatment of COVID-19, the company said on Monday. That would be the firm’s largest fundraising effort after it raised more than NT$1.4 billion from an initial public offering on the Taipei Exchange (TPEX) in April 2017, chief financial officer Sarah Chang (張小萍) told the Taipei Times by telephone. The price of the new shares would depend on the firm’s average share price